Fr1da Insulin Intervention

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

December 11, 2015

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Stage 1 Diabetes Mellitus, Type 1
Interventions
DRUG

Oral Insulin

Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period. Follow-up will continue for 24 months after the last administration of treatment.

OTHER

Placebo

Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose). Follow-up will continue for 24 months after the last administration of treatment.

Trial Locations (1)

80804

Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, Lehrstuhl für Diabetes und Gestationsdiabetes, der Technischen Universität München, München

All Listed Sponsors
collaborator

Technische Universität Dresden

OTHER

collaborator

Ludwig-Maximilians - University of Munich

OTHER

collaborator

Helmholtz Zentrum München

INDUSTRY

lead

Technical University of Munich

OTHER

NCT02620072 - Fr1da Insulin Intervention | Biotech Hunter | Biotech Hunter